The combination of venetoclax + ivosidenib (IDH1 inhibitor), with or without azacitdine is being explored in a Phase 1b/2 trial of patients with relapsed/refractory AML or treatment-naïve patients not fit for intensive chemotherapy (NCT03471260). The gene discussed is IDH1; the disease is acute myeloid leukemia.